Patents matching “combination”

US 11771752

Composition for oral or nasal delivery of tetanus, diphtheria, and pertussis vaccine alone or in combination using neurotoxin associated proteins

Prime Bio, Inc. · Granted Oct 3, 2023 · Expires Sep 28, 2043

US 11744816

Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease

Esperion Therapeutics, Inc. · Granted Sep 5, 2023 · Expires Aug 31, 2043

US 11746152

Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated PD-L1

The Board of Regents of the University of Texas System · Granted Sep 5, 2023 · Expires Aug 31, 2043

US 11714089

Combination of markers for diagnosing cancer

The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center · Granted Aug 1, 2023 · Expires Jul 27, 2043

US 11712474

Reduction of post-surgery cancer metastasis by combination of cannabidiol and NR2F6 inhibition

Regen Biopharma, Inc. · Granted Aug 1, 2023 · Expires Jul 27, 2043

US 11679112

Cancer treatments using combinations of CDK and ERK inhibitors

Biomed Valley Discoveries, Inc. · Granted Jun 20, 2023 · Expires Jun 15, 2043

US 11666574

Combination therapy involving diaryl macrocyclic compounds

TURNING POINT THERAPEUTICS, INC. · Granted Jun 6, 2023 · Expires Jun 1, 2043

US 11660330

Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy

VACCINEX, INC. · Granted May 30, 2023 · Expires May 25, 2043

US 11654193

Cancer treatment combinations

The Regents of the University of California · Granted May 23, 2023 · Expires May 18, 2043

US 11654145

Combination therapy involving diaryl macrocyclic compounds

TURNING POINT THERAPEUTICS, INC. · Granted May 23, 2023 · Expires May 18, 2043

US 11654157

Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation

Shuttle Pharmaceuticals, Inc. · Granted May 23, 2023 · Expires May 18, 2043

US 11648211

Nanoencapsulated combination drug formulations

Northwestern University · Granted May 16, 2023 · Expires May 11, 2043

US 11633385

Combination compositions for treatment of cancer

RedHill Biopharma Ltd. · Granted Apr 25, 2023 · Expires Apr 20, 2043

US 11618784

Anti-CD47 combination therapy

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Apr 4, 2023 · Expires Mar 30, 2043

US 11612575

Combination therapies with disulfiram

Spring Discovery, Inc. · Granted Mar 28, 2023 · Expires Mar 23, 2043

US 11596696

Combination therapy with an anti-CD25 antibody-drug conjugate

ADC THERAPEUTICS SA · Granted Mar 7, 2023 · Expires Mar 2, 2043

US 11590154

Triple antibiotic fixed-dose combination products, dosing regimen, methods, and kits for treating pulmonary non-tuberculosis mycobacterial infections

RedHill Biopharma Ltd. · Granted Feb 28, 2023 · Expires Feb 23, 2043

US 11572408

Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modulating agent

VACCINEX, INC. · Granted Feb 7, 2023 · Expires Feb 2, 2043

US 11564927

Therapeutic compositions, combinations, and methods of use

VERASTEM, INC. · Granted Jan 31, 2023 · Expires Jan 26, 2043

US 11566076

Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers

Five Prime Therapeutics, Inc. · Granted Jan 31, 2023 · Expires Jan 26, 2043

US 11559583

Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for cancer

Five Prime Therapeutics, Inc. · Granted Jan 24, 2023 · Expires Jan 19, 2043

US 11542312

IL-2 superagonists in combination with anti-PD-1 antibodies

Medicenna Therapeutics Inc. · Granted Jan 3, 2023 · Expires Dec 29, 2042

US 11529360

Natural combination hormone replacement formulations and therapies

Compass Therapeutics LLC · Granted Dec 20, 2022 · Expires Dec 15, 2042

US 11529340

Combination for treating pain

Regents of the University of Minnesota · Granted Dec 20, 2022 · Expires Dec 15, 2042